The GLP-1 Bridge Program: Price Fixing vs. Free Market Healthcare
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
The GLP-1 Bridge Program: Price Fixing vs. Free Market Healthcare
-
Letto da:
-
Di:
In this episode of the Health Policy Podcast, host Brian Hyde speaks with Jay Goldberg, North American Affairs Manager at the Consumer Choice Center, about the GLP-1 Bridge Program. While the program aims to make weight loss drugs like GLP-1s more affordable for Medicare and Medicaid recipients, Goldberg argues it exemplifies government price fixing. He explains how artificially lowering drug prices can disincentivize medical innovation and lead to slower access to new medications, drawing parallels to healthcare systems in other countries. Goldberg advocates for free-market competition as the most effective and sustainable way to reduce drug costs and foster innovation, ultimately benefiting consumers and the healthcare system more broadly.